Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?

To say this has been a big year for Summit Therapeutics (NASDAQ: SMMT) would be a huge understatement. The stock has risen over 600% since the end of 2023, thanks to surprisingly positive trial results for a cancer therapy called ivonescimab.The stock market has been pushing up Summit's stock price because there's a chance that ivonescimab could unseat Merck's Keytruda as the world's top-selling cancer treatment. Keytruda racked up a stunning $25 billion in sales last year, so there's a lot to be gained if Summit's candidate continues to succeed.Summit Therapeutics is on the right path, but it could be too early to predict buckets of incoming revenue. Its candidate isn't even approved in the territories where Summit intends to sell it.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool